# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN-TD
- Date: 1947-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review of contamination fears and codeine use, seen the same day by psychiatry. **S**

## History of present illness

Mr. Hughes returns one week after intake and is seen by Dr. Bachmann-Adeyemi of psychiatry on the same day. He took his last acetaminophen-codeine tablet about 20 hours ago, as planned for starting buprenorphine today, and has taken no more than the prescribed eight tablets a day this week. He has yawning, aching, a runny nose and gooseflesh. The contamination fears and washing are unchanged, at about four hours a day; he washed his hands eleven times before coming in. He completed the PCL-5 about the crash. The intake urine test, done with his consent, was positive for codeine and morphine, as expected, and negative for fentanyl, other opioids, benzodiazepines and other drugs. The prescription monitoring report showed acetaminophen-codeine from two prescribers at two pharmacies and no other controlled drugs. HIV, hepatitis C and hepatitis B tests were negative; he is not immune to hepatitis B. He has taken his unused codeine tablets to a pharmacy take-back. **S**

| Element | Detail |
|---|---|
| Last codeine | About 20 hours ago |
| Withdrawal | COWS 13, moderate |
| Rituals | About four hours a day; Y-BOCS 28 |
| Intake results | Urine positive for codeine and morphine only, negative for fentanyl; two prescribers on the monitoring report; HIV, hepatitis B and C negative; hepatitis B not immune |
| PCL-5 | 18, below the cut point |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Aching and restless since this morning |
| Gastrointestinal | Positive | Mild cramping; no vomiting or diarrhea |
| Musculoskeletal | Positive | Chest wall, left shoulder and low back pain |
| Psychiatric | Positive | Contamination fears and washing unchanged; no hallucinations; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff **S**
- Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Sertraline 50 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/80 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 72.3 kg; BMI 19.8 kg/m². All vital signs are synthetic.

PCL-5: 18. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Alert, restless, yawning; blood pressure 124/80, pulse 88; weight 72.3 kg |
| Eyes | Pupils 5 mm, reactive; mild tearing |
| Skin | Gooseflesh on the arms; hands red and cracked from washing; healed burn scars |
| Musculoskeletal | Tenderness over healed rib fractures on the left; left shoulder elevation limited to 120 degrees by pain |
| Psychiatric | Anxious and courteous; contamination obsessions with washing and avoidance; says the fears are probably excessive; no psychotic features; no suicidal or homicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Obsessive-compulsive disorder, contamination type, with good or fair insight** (F42.2). Dr. Bachmann-Adeyemi confirms obsessive-compulsive disorder with good or fair insight: the obsessions are unwanted and intrusive, the washing and avoidance are aimed at preventing contamination, and they take about four hours a day. It is not obsessive-compulsive personality disorder, illness anxiety disorder, post-traumatic stress disorder (PCL-5 18) or a psychotic disorder. Y-BOCS 28, severe. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Sertraline 50 mg daily, with a plan to raise the dose every four to six weeks toward 200 mg.
   - Exposure and response prevention with the clinic psychologist, weekly 90-minute sessions, starting next week.
   - With his written consent, his personal assistant will join two therapy sessions to learn how staff can stop carrying out rituals for him.
2. **Opioid use disorder, moderate** (F11.20). COWS 13 about 20 hours after the last codeine dose, so buprenorphine can start without precipitating withdrawal. He chose buprenorphine after hearing the options, including a slow codeine taper. **S**
   - Buprenorphine with naloxone 4 mg in the clinic, a further 4 mg two hours later, and up to 4 mg more this evening if needed; 8 mg twice daily from tomorrow.
   - Dispensed one week at a time; naloxone at home.
   - No benzodiazepines.
3. **Chronic pain after major trauma** (G89.21). Codeine combination tablets have stopped, so acetaminophen is given on a schedule instead. **S**
   - Acetaminophen 1,000 mg three times daily, no more than 3,000 mg a day.
   - Physical therapy for the chest wall, left shoulder and low back, twice weekly.
4. **Weight loss** (R63.4). Weight 72.3 kg; he eats one meal a day that he has watched being made. **S**
   - Dietitian visit next week; meals will become part of the exposure plan.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 28 (obsessions 14, compulsions 14), confirmed by psychiatry; about four hours a day |
| Survey | Post-traumatic stress after the crash (PCL-5) | Once, at diagnosis | Completed today | PCL-5 18, below the cut point of 31 to 33; no post-traumatic stress disorder |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Baseline before sertraline: sodium 139 mmol/L at intake, no anticoagulant or NSAID, no history of mania; told to report restlessness or any new thoughts of suicide |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Ordered | Weekly sessions with the clinic psychologist booked from next week |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Ordered | Written consent signed for his assistant to join two sessions; staff will not be asked to report on him |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Up to date | PHQ-9 9 (item 9 scored 0) and GAD-7 12 at intake; repeat at five weeks |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone; codeine taken to the take-back |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No more than eight codeine tablets a day this week; last dose 20 hours ago; COWS 13; buprenorphine started in clinic |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Up to date | Intake test positive for codeine and morphine, negative for fentanyl, other opioids, benzodiazepines and other drugs; next at five weeks |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Checked today before buprenorphine: the codeine from two prescribers seen at intake and nothing new; the other prescriber informed with his consent |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home; two of his staff shown how to use it |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Up to date | PEG 6.7 at intake; repeat at five weeks |
| Referral | Physical therapy and graded activity | Twice weekly | Ordered | Physical therapy booked |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 72.3 kg, BMI 19.8; dietitian next week |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Creatinine 0.94 mg/dL, eGFR 104, urine albumin-to-creatinine ratio 8 mg/g, AST 31, ALT 38 and albumin 3.7 g/dL at intake |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Ordered | Audiogram booked for the morning of the five-week visit |
| Referral | Psychiatry consultation | At diagnosis | Completed today | Seen by Dr. Bachmann-Adeyemi today |

## Goal progress

- Y-BOCS down by at least 35 percent (response) within six months. In progress; target 1947-10-05. **S**
- Stop codeine and stay on buprenorphine with no use of other opioids. In progress; target 1947-10-05. **S**
- Pain that lets him work and sleep: PEG at or below 4. In progress; target 1947-10-05. **S**
- Regain weight to at least 76 kg with regular meals. In progress; target 1947-10-05. **S**
- Follow conversation in meetings with hearing aids. In progress; target 1947-10-05. **S**
- Staff stop carrying out rituals for him, step by step, by his own plan. In progress; target 1947-10-05. **S**

## Medication changes

- Stopped: Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a day **S**
- Started: Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day **S**
- Started: Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Started: Sertraline 50 mg oral tablet, one tablet daily **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association (American Journal of Psychiatry 2007;164(7 Suppl):5-53)
- Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Hearing loss in adults: assessment and management (NG98) (2018), National Institute for Health and Care Excellence
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Telephone check tomorrow after the second day of buprenorphine. Five-week review with the audiogram that morning. Call the clinic or 988 at any time; use naloxone and call 911 for heavy sleepiness or slow breathing. **S**
- Next scheduled visit 1947-06-08: five-week review: OCD treatment, buprenorphine, pain, the audiogram and weight. **S**
